COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,742 Articles (22,502 medRxiv, 8,240 bioRxiv)

Most recent first Previous |  Page 2882: Articles 28811-28820  | Next

SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy
Benelli, G., Buscarini, E., Canetta, C., La Piana, G., Merli, G., Scartabellati, A., Vigano, G., Sfogliarini, R., Melilli, G., Assandri, R., Cazzato, D., Rossi, D. S., Usai, S., Caldarelli, G., Gili, T., Tramacere, I., Pellegata, G., Lauria, G.
10.1101/2020.04.14.20053090 — Posted: 2020-04-20
Proteome-wide analysis of differentially-expressed SARS-CoV-2 antibodies in early COVID-19 infection
Zhang, X., Wu, X., Wang, D., Lu, M., Hou, X., Wang, H., Liang, T., Dai, J., Duan, H., Xu, Y., Li, Y., Yu, X.
10.1101/2020.04.14.20064535 — Posted: 2020-04-20
Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers
Shental, N., Levy, S., Skorniakov, S., Wuvshet, V., Shemer-Avni, Y., Porgador, A., Hertz, T.
10.1101/2020.04.14.20064618 — Posted: 2020-04-20
Trends and prediction in daily incidence and deaths of COVID-19 in the United States: a search-interest based model
Yuan, X., Xu, J., Hussain, S., Wang, H., Gao, N., Zhang, L.
10.1101/2020.04.15.20064485 — Posted: 2020-04-20
Interplay of host regulatory network on SARS-CoV-2 binding and replication machinery
Shiek, A., Paramasivam, P., Raj, K., Kumar, V.
10.1101/2020.04.20.050138 — Posted: 2020-04-20
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Ma, C., Hurst, B., Hu, Y., Szeto, T., Tarbet, B., Wang, J.
10.1101/2020.04.20.051581 — Posted: 2020-04-20 Discussion: Onsite
Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays
Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., Pettie, D., King, N. P., Balazs, A. B., Bloom, J. D.
10.1101/2020.04.20.051219 — Posted: 2020-04-20 Discussion: Onsite
Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis
Yazdani, Z., Rafiei, A., Yazdani, M., Valadan, R.
10.1101/2020.04.20.051557 — Posted: 2020-04-20
Phylodynamics of SARS-CoV-2 transmission in Spain
Diez Fuertes, F., Iglesias Caballero, M., Monzon, S., Jimenez, P., Varona, S., Cuesta, I., Zaballos, A., Thomson, M. M., Jimenez, M., Garcia Perez, J., Pozo, F., Perez Olmeda, M., Alcami, J., Casas, I.
10.1101/2020.04.20.050039 — Posted: 2020-04-20
Limited SARS-CoV-2 diversity within hosts and following passage in cell culture
Moreno, G. K., Braun, K. M., Halfmann, P. J., Prall, T. M., Riemersma, K. K., Haj, A. K., Lalli, J., Florek, K. R., Friedrich, T. C., Kawaoka, Y., O'Connor, D. H.
10.1101/2020.04.20.051011 — Posted: 2020-04-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).